Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)’s share price shot up 3.6% during mid-day trading on Monday . The stock traded as high as $76.33 and last traded at $75.42, with a volume of 487,148 shares changing hands. The stock had previously closed at $72.78.

Several brokerages have recently issued reports on ALNY. Needham & Company LLC reiterated a “buy” rating and set a $152.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, August 5th. Cowen and Company restated a “buy” rating and issued a $150.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday, August 7th. Goldman Sachs Group Inc. restated a “neutral” rating and issued a $65.00 target price (up from $63.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 10th. Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Tuesday, August 9th. Finally, Morgan Stanley assumed coverage on Alnylam Pharmaceuticals in a report on Tuesday, August 2nd. They issued an “overweight” rating and a $93.00 target price on the stock. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $113.62.

The stock’s 50 day moving average price is $68.95 and its 200-day moving average price is $63.82. The stock’s market capitalization is $6.61 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.24) by $0.19. The firm had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.09 million. During the same period in the prior year, the company posted ($0.85) EPS. The firm’s quarterly revenue was up .2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals Inc. will post ($4.69) EPS for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares of the company’s stock, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

An institutional investor recently raised its position in Alnylam Pharmaceuticals stock. BlackRock Advisors LLC boosted its stake in Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) by 8.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 179,529 shares of the biopharmaceutical company’s stock after buying an additional 13,612 shares during the period. BlackRock Advisors LLC owned approximately 0.21% of Alnylam Pharmaceuticals worth $16,901,000 at the end of the most recent quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.